Table 2.
Clinical and mycologic potency of nystatin and the control treatments.
| Authors | Risk Factors | Clinical Cure Rates | Mycological Cure Rates | ||
|---|---|---|---|---|---|
| Nystatin | Controls | Nystatin | Controls | ||
| Afroozi et al. 2019 [28] | Denture | 89.30% | 53.60% | - | - |
| Alrabiah et al. 2019 [29] | Denture | - | - | - | - |
| Alves et al. 2020 [30] | Denture | 54.20% | 53.30% | - | - |
| Bakhshi et al. 2012 [31] | Denture | - | - | - | - |
| Araújo et al. 2021 [35] | Denture | 89% | 61% | 83% | 33% |
| Gonoudi et al. 2021 [32] | Denture | - | - | - | - |
| Johnson et al. 1989 [39] | Denture | 28.60% | 0 | 57.10% | 0 |
| 14.30% | 0 | 71.40% | 0 | ||
| Labban et al. 2021 [33] | Denture | - | - | - | - |
| Li et al. 2014 [34] | Denture | - | - | 30.77% | 20% |
| Mima et al. 2012 [40] | Denture | 53% | 45% | - | - |
| Nairn et al. 1975 [37] | Denture | 76.90% | 88.80% | 40% | 6.25% |
| 76.90% | 40% | 40% | 20% | ||
| Pinelli et al. 2013 [38] | Denture | - | - | - | - |
| Silva et al. 2012 [36] | Denture | 18.75% | 23.53% | - | - |
| 18.75% | 22.22% | - | - | ||
| Sanita et al. 2012 [42] | Denture in diabetic patients | 20% | 25% | - | - |
| Thompson et al. 1986 [41] | Respiratory disease and dentures | 87% | 80% | - | - |
| Goins et al. 2002 [44] | Infants | 28.60% | 100% | 5.60% | 73.30% |
| Hoppe et al. 1996 [45] | Infants | 42.80% | 85.10% | 20% | 29.60% |
| 48.50% | 85.10% | 3.00% | 29.60% | ||
| Hoppe 1997 [46] | Infants | 54.10% | 99% | 8.20% | 54.10% |
| Flynn et al. 1995 [43] | Infants, Children | 51% | 91% | 11% | 76% |
| Meunier et al. 1990 [51] | Cancer patients | 72% | 87% | 24% | 61% |
| Mukherjee et al. 2017 [47] | HIV | 67.80% | 68.50% | - | - |
| Pons et al. 1997 [49] | HIV, AIDS | 52% | 87% | 6% | 60% |
| Nyst et al. 1992 [48] | AIDS | 9% | 42% | 13% | 62% |
| 9% | 43% | 13% | 57% | ||
| Blomgren et al. 1998 [50] | Multigroup patients | 16.70% | 30% | - | - |